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Summary
The management of headaches with juvenile onset pres-
ents several problems, related not only to appropriate
drug selection but also to the specific features distin-
guishing headache disorders in children and adoles-
cents: a child is not a “little adult”. Many age-related fac-
tors influence the clinical expression of headache and
these should be taken into account not only in the treat-
ment, but also in the diagnosis, of juvenile headache.
Few randomised placebo-controlled clinical trials of
acute or preventive drugs have been conducted in paedi-
atric headache patients, and those that have show a high
placebo response rate in children (e.g. up to 55% for pro-
phylactic drugs and up to 69% for symptomatic ones).
The available data on symptomatic drugs are present-
ed and discussed, focusing, in particular, on mecha-
nisms of action, evidence of efficacy, and tolerability.
KEY WORDS: acute treatment, adolescence, childhood, migraine,
review.
Introduction
Migraine can be regarded as an episodic-chronic disor-
der (1). The therapeutic approach to migraine should
cover not only treatment of attacks but also, in many
cases, preventive treatment. 
Even when prophylactic treatment of migraine is suc-
cessful the patient will, in most cases, still suffer some
migraine attacks and need treatment for these (2).
A recent study has found that children obtaining ade-
quate relief from pain and associated symptoms by rest-
ing in a darkened, quiet room and sleeping for a few
hours may not require pharmacotherapy (3). However,
the benefits of sleeping for a few hours have to be set
against the activity that is lost as a result of it; moreover,
in view of the complex and bidirectional association be-
tween migraine and cerebrovascular disease (4), a spe-
cific therapy might be beneficial in preventing complica-
tions of migraine.
In view of these considerations, the use of a mild anal-
gesic could be recommended to try to speed up relief. 
The aim of symptomatic treatment of migraine is to re-
lieve moderate or severe migraine pain (5), and to alle-
viate other symptoms, such as nausea and vomiting.
Acute treatment should be used on a maximum of three
to four days a month.
The management of headaches with juvenile onset
presents several problems, related not only to appropri-
ate drug selection but also to the specific features distin-
guishing headache disorders in children and adoles-
cents: a child is not a “little adult”. Many age-related fac-
tors influence the clinical expression of headache and
these should be taken into account not only in the treat-
ment, but also in the diagnosis, of juvenile headache.
Children seem to find it difficult to describe their
headache, and questions regarding the onset of the
headache history, as well as the duration and frequency
of headaches, are answered more reliably by parents
(6). This also applies to the history of migraine precur-
sors (i.e. cyclical vomiting, abdominal migraine, and be-
nign paroxysmal vertigo of childhood) (7). There are
strategies that can be usefully adopted to help improve
migraine diagnosis in children: 
i) take as long as you need to take the history, remem-
bering to exercise patience and to use age-appropriate
terminology; 
ii) instruct the patient or the patient’s parents to keep an
appropriate headache diary (e.g. recording the main
headache characteristics and associated symptoms)
over a period of some weeks to document the headache
frequency and duration, the degree of disability induced,
and the occurrence of associated symptoms, as well as
the use of medications;
iii) ask the child to draw a picture of what his or her
headache feels like, in accordance with the suggestion
of Stafstrom et al. (8), who showed that children’s
headache drawings are useful in the diagnosis of
headache type and provide valuable insights into their
experience of pain. An adolescent, on the other hand, is
usually able to give a detailed description of his or her
headache and answers all questions adequately (6).
Moreover, headache occurring in childhood and adoles-
cence rarely presents the characteristics typically found
in adult headache (6,9-12). 
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This observation led to several proposals – e.g. Lanzi
(13) – for modification of the diagnostic criteria set out
in the 1988 International Headache Society (IHS) clas-
sification of headache (14). Indeed, the recently re-
vised version of this classification (the International
Classification of Headache Disorders-II, ICHD-II) in-
cludes criteria that better reflect the peculiarities of mi-
graine with and without aura (MA and MwA, respec-
tively) in childhood and adolescence (Table I), such as
the minimum attack duration of 1 hour and the bilater-
al location of the pain (15). Nevertheless, it has been
demonstrated that, in spite of the introduction of notes
to take into account the situation of children and ado-
lescents, the ICHD-II criteria are poorly applicable to
children under six years of age (16). Therefore, the de-
velopment of alternative criteria, better able to take in-
to account the peculiarities of early-onset headache
forms (such as duration of < 1 h for MwA), would seem
to be useful and opportune (17). 
Table I - International Classification of Headache Disorders
(ICHD)-II. Diagnostic criteria for paediatric migraine without
aura.
• At least five attacks fulfilling criteria B-D
• Attacks lasting 1-72 h
• Headache has at least two of the following characteris-
tics:
i) either bilateral or unilateral location
ii) pulsating quality
iii) moderate or severe pain intensity
iv) aggravated by routine physical activities
• At least one of the following accompanies headache:
i) nausea and/or vomiting
ii) phonophobia and photophobia (may be inferred from
children’s behaviour)
Once a diagnosis has been definitely established,
headache should be treated as early as possible, both
to prevent its escalation and to increase the effective-
ness of medication. 
The presence of aura or of prodrome symptoms can
help patients to optimise the timing of drug intake. Im-
portant considerations, particularly in childhood and
adolescence, are the risks of medication overuse and of
self-treatment without parental control (18). 
It is important, before selecting an appropriate treatment
for childhood and adolescent migraine, to be aware of
medications that have shown efficacy in adults, but
whose safety and efficacy have not been assessed in
younger patients (children and adolescents) (19). In
fact, few randomised placebo-controlled clinical trials,
either of acute or of preventive drugs, have been con-
ducted in paediatric headache patients.
Moreover, the few studies that have been published
have shown high placebo response rates in children
(e.g. up to 55% for prophylactic drugs and up to 69%
for symptomatic ones; Table II), and because these
high placebo response rates drastically reduce the
possibility of finding effective agents, drug companies
and independent researchers have little interest in
performing new pharmacological clinical trials in this
field.
On the other hand, the placebo effect is a psychobiolog-
ical phenomenon that can be attributed to different
mechanisms (20), and it has to be taken into account;
the physician should bear in mind that all medical treat-
ment is set in a psychosocial context that affects the
therapeutic outcome.
The available efficacy data on symptomatic drugs are
summarised in Table II and these drugs will be dis-
cussed in detail, focusing in particular on their different
mechanisms of action, and on evidence of their efficacy
and tolerability.
Medication for an acute attack can be specific or non-
specific (21). Non-specific medications are used to con-
trol the pain and associated symptoms of migraine but
they are also used in other pain disorders; specific med-
ications, on the other hand, control the migraine attack
but are not useful for non-headache pain disorders.
Non-specific acute headache medications include anal-
gesics (non-steroidal anti-inflammatory drugs, NSAIDs,
and combination analgesics) and antiemetics. Specific
acute headache medications include dihydroergotamine
and selective 5-HT1 agonists (triptans).
Non-specific medications
Acetaminophen and NSAIDs
The analgesic effects of acetaminophen are likely to be
mediated centrally, but the mechanism is unclear (22).
An indirect involvement of spinal serotonin receptors
has been suggested (23,24).
As with all the NSAIDs, ibuprofen inhibits prostaglandin
synthesis via inhibition of cyclooxygenase, thus reduc-
ing the hypothesised neurogenically-mediated inflam-
matory process in migraine (25). 
Hämäläinen (26) compared acetaminophen (15 mg/kg)
with ibuprofen (10 mg/kg) in a double-blind, placebo-
controlled, single-dose, three-way crossover study and
showed that both drugs were well tolerated and effective
in relieving migraine attacks. At 1 hour, acetaminophen
tended to be slightly more effective (39% of children re-
lieved) than ibuprofen (37% of children relieved), but at
2 hours after administration, ibuprofen was more effec-
tive than acetaminophen (68% and 54% of children ob-
taining relief on ibuprofen and acetaminophen, respec-
tively vs 37% for placebo). 
A more recent study also showed that a lower ibuprofen
dosage (7.5 mg/kg) is more effective than placebo in re-
ducing headache severity at 2 hours (76% versus 53%;
p=0.006) (27). 
Evers et al. (28) conducted a trial to investigate the effi-
cacy of oral zolmitriptan and ibuprofen in the treatment
of migraine in children and adolescents. The authors
found that ibuprofen (200 to 400 mg) was more effective
than placebo in providing pain relief after 2 hours (28%
for placebo versus 69% for ibuprofen; p<0.05). 
The efficacy and safety of other NSAIDs (e.g. acetylsal-
icylic acid, diclofenac, naproxen, mefenaminic acid) in
the treatment of migraine in children and adolescents
have still not been assessed. 
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Antiemetics
The associated symptoms of migraine, such as nausea
and vomiting, can be as disabling as the headache pain
itself. The gastric stasis and delayed gastric emptying
that are associated with migraine can decrease the ef-
fectiveness of oral medications (29).
Early administration of analgesics in the course of a
migraine attack seems to alleviate nausea as well as
pain.
Dopamine antagonists such as metoclopramide and
prochlorperazine may, exploiting their antiemetic, antis-
erotonergic, antiadrenergic, and anticholinergic proper-
ties, relieve migraine symptoms. 
Metoclopramide or prochlorperazine may be used to
alleviate nausea and vomiting in migraine, but there is
a lack of controlled trials on their use in children.
The use of such medications can be complicated by ex-
trapyramidal and dystonic reactions, which usually dis-
appear after withdrawal of the drug.
Acute migraine treatment in children and adolescents
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Table II - Symptomatic drugs evaluated in placebo-controlled and open clinical trials.
Drug Dose Age n. % of responders* p Ref. Notes
range
Non-specific drugs 
Ibuprofen 10 mg/kg 4-16 y 88 68% 37% <0.05 26
7.5 mg/kg 6-12 y 84 76% 53% 0.006 27
200-400 mg 6-18 y 32 69% 28% <0.05 28
Acetaminophen 15 mg/kg 4-16 y 88 54% 37% <0.05 26
Specific drugs
Dihydroergotamine 20 µg/kg and 5-15 y 12 58% 16% NS 32
40 µg/kg
Sumatriptan nasal 20 mg 6-10 y 14 86% 43% 0.03 35
5/10/20 mg 12-17 y 510 66%§ 53% <0.05 36
10-20 mg 8-17 y 83 64% 39% 0.003 37
20 mg 12-17 y 738 61% 52% NS 38 1 hour post-dose: 
primary end point.
42% 33% 0.046 30 min post-dose: 
secondary end point
68% 58% 0.025 2 hours post-dose: 
secondary end point
Sumatriptan oral 50-100 mg 8-16 y 23 30% 22% NS 31
Sumatriptan 3-6 mg 6-16 y 17 64% OT 33
subcutaneous 0.06 mg/kg 6-18 y 50 78% OT 34
Rizatriptan oral 5 mg 12-17 y 296 66% 56% NS 39
5 mg 12-17 y 234 68% 69% NS 39 Therapy on school-
days
74% 58% 0.002 Therapy also at week 
ends
Zolmitriptan oral 5 mg 12-17 y 686 77% OT 40
2.5/5 mg 12-17 y 38 88/70% OT 41
2.5 mg 6-18 y 32 62% 28% <0.05 28 
Almotriptan oral 6.25-12.5 mg 11-17 y 15 86% OT 42
Eletriptan 40 mg 12-17 y 267 57% 57% NS 44 Significant differences in 
secondary endpoints 
(see text)
Abbreviations: NS=non-significant difference (active drug vs placebo); RCT=randomised controlled trial; OT=open trial.
* the % is expressed as overall % of responders (OT) or active-drug vs placebo % of responders (RCT); § 5 mg.
Specific medications
Dihydroergotamine 
Dihydroergotamine (DHE) is an agonist of arterial sero-
tonin receptors and blocks α-adrenergic receptors. DHE
is hypothesised to exert an antimigraine effect by produc-
ing a powerful vasoconstriction of the external carotid ar-
tery and its branches, but also by a receptor-mediated
neural pathway and a serotonergic mechanism (30). 
Hämäläinen et al. conducted a stepwise series of stud-
ies: following the first acetaminophen and ibuprofen
comparison study (26), the children who had not re-
sponded to paracetamol and ibuprofen were entered in-
to two subsequent studies that assessed the effects of
sumatriptan (31) and DHE (32). In the children with
acetaminophen/ibuprofen-resistant migraine, DHE was
more effective than placebo, but the difference between
the treatments was not statistically significant (32). 
Triptans 
Triptan agents selectively stimulate vascular serotonin
5-HT1 receptors; they thus relieve pain by constricting
the affected vessels and blocking nociceptive impulses,
and the subsequent inflammatory response. 
The triptans are thought to act predominantly as 
5-HT1B/D receptor agonists, although their therapeutic
effect may also be mediated through binding to other
receptor subtypes. During a migraine attack, triptans,
by stimulating the 5-HT1B receptors on cranial blood
vessels, are thought to induce vasoconstriction that is
relatively selective for these vessels, given that vaso-
constriction in the peripheral circulation is mediated
mainly by 5-HT2 receptors.
In addition, triptans activate inhibitory presynaptic 
5-HT1D receptors located on the terminal endings of
trigeminal nociceptive afferents, effectively decreasing
the release of the neuropeptides responsible for vasodi-
latation of meningeal and cerebral blood vessels, and
for activation of second-order neurons in the trigeminal
nucleus caudalis. Recently, 5-HT1D receptors have
been shown to be present on postsynaptic second-order
neurons in the caudal trigeminal nucleus. Whether trip-
tans bind to and modulate the activity of these neurons
is not yet clear.
Sumatriptan. Sumatriptan has been investigated in sev-
eral clinical trials. The first studies (33,34) were non-
controlled trials of subcutaneously administered suma-
triptan, and they showed partial relief from migraine in
64 and 78% of patients, respectively. The first ran-
domised placebo-controlled trial (31) was conducted
with the aim of studying the effectiveness of oral suma-
triptan (50 to 100 mg) in children and adolescents with
acetaminophen-/ibuprofen-resistant migraine. In that
study, the response rates were lower than those demon-
strated in adult studies, and oral sumatriptan was not
more effective than placebo (31). 
More recently, four prospective, randomised, placebo-
controlled trials assessed both the efficacy and the safe-
ty of sumatriptan nasal spray in adolescent migraineurs
(35-38).
Ueberall (35) found significant headache relief at 2
hours in 85.7% of treated patients (20 mg sumatriptan
nasal spray) compared with 42.9% in the placebo group
(p=0.03).
Winner et al. (36) compared the effectiveness of 5-, 10-
and 20-mg sumatriptan nasal spray with placebo in 510
adolescents. The 2-hour response rate (reduction in
headache severity) was 66% for the 5-mg dose
(p<0.05), 63% for the 20-mg dose (p=0.059) and 53%
for placebo. Both photophobia and phonophobia were
reduced with the 20-mg dose (p<0.05). The only ad-
verse effect was taste disturbance (26%). 
Ahonen et al. (37) evaluated the effectiveness of suma-
triptan nasal spray in children aged 8-17 years (10 mg
for children weighing < 40 kg and 20 mg for children
weighing > 40 kg). The primary end point (reduction in
headache severity at 2 h) was met in 64% of the treated
patients and in 39% of the placebo group (p<0.003). In
addition, at 1 hour sumatriptan was more effective than
placebo in providing headache relief (51% versus 29%;
p<0.014). The most common adverse effect was, again,
taste disturbance (29%). 
The fourth trial was conducted by Winner et al. (38) to
compare the efficacy and tolerability of sumatriptan
nasal spray (5 and 20 mg) versus placebo in the acute
treatment of migraine in adolescent subjects. The study
was conducted because the previous randomised,
placebo-controlled study of 510 adolescent subjects
(36), had shown sumatriptan (5, 10 and 20 mg) to be
well tolerated. However, the primary efficacy analysis for
headache relief with 20 mg at 2 hours did not demon-
strate statistical significance (p=0.059). 
This more recent trial (38) was a randomised (1:1:1),
placebo-controlled, double-blind, parallel-group study. In
total, 738 adolescent subjects (mean age: 14 years) with
≥ 6-month histories of migraine (with or without aura)
self-treated a single attack of moderate or severe mi-
graine. The primary end points were headache relief at
1 hour and sustained relief from 1 to 24 hours. The au-
thors found that sumatriptan 20 mg provided greater
headache relief than placebo at 30 minutes (42% versus
33%, respectively; p=0.046) and at 2 hours post-dose
(68% versus 58%; p=0.025), but did not reach statistical
significance at 1 hour (61% versus 52%; p=0.087), or for
sustained headache relief from 1 to 24 hours (p=0.061).
Significant differences (p<0.05) in favour of sumatriptan
20 mg over placebo were observed for several second-
ary efficacy end points including sustained relief from 2
to 24 hours. In general, response rates to sumatriptan
nasal spray 5 mg were slightly higher than to placebo,
but the differences did not reach statistical significance.
Sumatriptan was well tolerated and no serious adverse
events occurred, taste disturbance being the most com-
mon adverse effect. 
Rizatriptan. Rizatriptan was studied by in a randomised,
placebo-controlled trial that included 296 adolescents
aged 12-17 years (39). No difference in pain relief was
found compared to placebo at the 2-h primary end point
(66% versus 56%; p=0.79). Tolerability and adverse
event rates were comparable with placebo. 
More recently, two studies were conducted in migraine
patients aged 12-17 years to examine the short- and
long-term efficacy and tolerability of rizatriptan 5 mg
(40). The first study was a randomised, double-blind,
placebo-controlled, single-attack study followed by a
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randomised, one-year, open-label extension. The sec-
ond was a randomised, one-year, open-label study. 
In the single-attack study, patients used rizatriptan 5-mg
tablets (n=234) or placebo (n=242) to treat a moderate
or severe migraine headache and up to two recur-
rences. The study medication had to be used only on
non-school days. 
In the one-year studies, patients were treated for up to
six migraine attacks per month with rizatriptan 5-mg
tablets (n=273), rizatriptan 5-mg wafers (n=281) or stan-
dard-care therapy (n=132). Headache severity was as-
sessed by the patient 2 hours after the initial dose. In all
the studies, the primary efficacy measure was pain relief
at 2 hours post-dose. In the single-attack study, the pro-
portion of patients reporting pain relief at 2 hours was
not significantly different between the rizatriptan 5 mg
(68.2%) and placebo (68.8%) arms. Fewer patients than
expected (~ 30%) treated their migraine attacks at the
weekend. Among these patients, the proportion with
pain relief at 2 hours was significantly higher in the riza-
triptan group than in the placebo group (74% versus
58%; p=0.022). 
In the multiple-attack studies, pain relief at 2 hours was
achieved in significantly more attacks treated with the
rizatriptan 5-mg tablet (77%) or with a rizatriptan 5-mg
wafer (77%) than with standard care (64%). Rizatriptan
5 mg was well tolerated. 
Zolmitriptan. Zolmitriptan was assessed in adolescents
(12-17 years of age) in an open-label multicentre trial
(41). Doses of 2.5 or 5.0 mg were used to treat 276 mi-
graine attacks reaching an overall response at 2 hours
of 88% and 70%, respectively. The treatment was well
tolerated. 
More recently, Evers et al. conducted a double-blind,
placebo-controlled, crossover study to investigate the ef-
ficacy of oral zolmitriptan in the treatment of migraine in
children and adolescents (28). Patients (n=32) received
placebo, zolmitriptan 2.5 mg and ibuprofen 200 to 400 mg
to treat three consecutive migraine attacks. Pain relief
rates at 2 hours were 28% for placebo, 62% for zolmitrip-
tan, and 69% for ibuprofen (placebo versus zolmitriptan
p<0.05; placebo versus ibuprofen p<0.05). Both drugs
were well tolerated with only mild side effects. 
Almotriptan. Almotriptan was studied in a small open-la-
bel pilot study in 15 patients with a history of migraine
with or without aura, aged 11-17 years (42). Almotriptan
in doses ranging from 6.25 to 12.5 mg was well tolerat-
ed (no adverse effects except for one case of transient
mild stiffness). Of the 15 patients, only two demonstrat-
ed no efficacy without adverse effects. In the other 13
patients almotriptan was effective. 
Naratriptan. Naratriptan has not been assessed for effi-
cacy in a clinical trial involving children and adolescents.
The only study of this drug conducted to date set out to
characterise its pharmacokinetics for 2.5-mg tablets in
adolescents (43). No serious adverse events were ap-
parent. 
Eletriptan. Eletriptan, a potent 5-HT1B/1D agonist, has
proven efficacy in the acute treatment of migraine in
adults.
Winner et al. (44) evaluated the efficacy and tolerability
of eletriptan 40 mg versus placebo in adolescent pa-
tients (aged 12-17) in a multicentre, double-blind, paral-
lel-group, placebo-controlled trial. 
The primary efficacy endpoint was 2-hour headache re-
sponse. Of 274 patients who treated a migraine attack,
267 were evaluated (n=138 eletriptan; n=129 placebo).
The authors found no significant difference in 2-hour
headache response for eletriptan 40 mg versus placebo
(57% vs 57%), and, moreover, no significant improve-
ments were observed for any of the outcomes at 1 or 2
hours post-dose. The authors found a significant advan-
tage for eletriptan 40 mg in reducing headache recur-
rence within 24 hours post-dose (11% vs 25%,
p=0.028), and post hoc analyses showed statistically
significant differences for sustained headache response
rates (52% vs 39%; p=0.04) and sustained pain-free re-
sponse rates (22% vs 10%; p=0.013). The strongest
clinical predictor of placebo response was triptan-naive
status (i.e. no previous use of any triptan). 
Eletriptan 40 mg was well tolerated in this population,
and the profile of adverse events was similar to that ob-
served in phase III trials in adult patients.
Adverse events
Acetaminophen is considered a safe drug and, if used in
therapeutic doses, adverse events are extremely rare,
although their exact incidence is unknown. Overdoses
can occur and are associated with hepatotoxicity and
renotoxicity. The potential adverse effects of ibuprofen
are similar to those of other NSAIDs. However, gastroin-
testinal bleeding, renal failure or anaphylaxis are rare
with short-term use in children (26). Sumatriptan is well
tolerated; no serious adverse events occurred in clinical
trials, taste disturbance emerging as the most common
adverse effect (35-38). 
Discussion
The available published data on the efficacy and safety
of symptomatic drug treatment for migraine in children
and adolescents (summarised in Table II) suggest that
ibuprofen (7.5 to 10.0 mg/kg) and acetaminophen 
(15 mg/kg) are effective treatments and should be con-
sidered. Sumatriptan nasal spray (5 and 20 mg) is also
probably effective, but should be considered for the
treatment of adolescents only. 
There are not yet sufficient data to allow the use of oth-
er NSAIDs and triptans to be recommended for the
treatment of migraine in children and adolescents. 
As also shown by the high impact of the placebo effect
on migraine-treatment efficacy, headache, which results
from an interaction between biological, psychological
and environmental factors, is a complex condition, both
pathogenetically and clinically; this is particularly true in
childhood and adolescence. 
The role of psychological factors, life events and exces-
sively stressful lifestyles in influencing recurrent
headache has been outlined repeatedly (3,36,45,47). In
a population study, Anttila et al. (48) showed that 28.8%
of migraine patients had internalising symptom scores
above the cut-off point of normal functioning. Other re-
search, using not only behavioural check-lists compiled
Acute migraine treatment in children and adolescents
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by parents, but also more in-depth psychodiagnostic
evaluations, found higher rates of psychiatric comorbidi-
ties in children with persistent headache compared with
headache-free patients (78% versus 31%) after a long
follow-up period (16). Thus, alongside the right choice of
drug therapy, it is also mandatory to look for possible
psychiatric comorbidities linked to the headache, and
factors generating stress or psychological distress. A
good review on this issue draws attention to the high
number of person-specific and situational variables that
influence headache (49). Indeed, it has been demon-
strated that headache is the most frequent somatic
symptom in children and adolescents referred for emo-
tional and behavioural disorders, as well as in patients
with depression and/or anxiety (50). 
Moreover, as a consequence of the headache, psy-
chosocial functioning may be impaired in various areas,
including family life, relations with the peer group and
friends, leisure activities and working capacity, and pro-
ductivity at school or at work (45).
In conclusion, the clinical approach to the child or adoles-
cent with acute migraine, and to his/her parents, should
be holistic. Migraine in childhood and adolescence, as in
adulthood, is a disorder highly influenced by biological
variables: genetic predisposition, electrochemical and
neurobiochemical events, vascular or blood flow modifi-
cations. Future advances in the field of migraine genetics
could provide new insight into the pathophysiology of mi-
graine and thus new treatment options (51). 
In our experience the migraine attack in childhood, un-
like adulthood, can also be closely linked to psychologi-
cal variables: specific life events and/or constitutional
predisposition, can play a significant role in the genesis
and evolution of the pain. As a result, the patient-clini-
cian relationship is often a central factor in the therapy,
even influencing the course of the disease (18). 
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